Fungal Infection in Patients in Intensive Care Units
Predictors of Fungal Infection in Non-neutropenic Patients in Intensive Care Units
1 other identifier
interventional
150
0 countries
N/A
Brief Summary
Predictors of fungal infection in non-neutropenic patients in intensive care units and the aim of the study is To evaluate the frequency of fungal infection in non-neutropenic patients in Intensive Care Units. To evaluate the risk factors of fungal infection in these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 21, 2020
CompletedFirst Posted
Study publicly available on registry
December 24, 2020
CompletedStudy Start
First participant enrolled
January 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2022
CompletedDecember 28, 2020
December 1, 2020
1 year
December 21, 2020
December 23, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
frequency of fungal infection in cirrhotic patients
frequency of fungal infection in cirrhotic patients
4 months
Study Arms (1)
cirrhotic ICU Patients
EXPERIMENTALabout 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.
Interventions
1. Complete blood picture 2. Liver function test and prothrombine time \& concentration. 3. Blood urea and creatinine 4. Blood glucose, serum Na and K 5. CRP and ESR 6. Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers
Eligibility Criteria
You may qualify if:
- Adult Patients with liver cirrhosis that will be clinically suspected to have in- fection.
You may not qualify if:
- Age \< 18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet. 2006 Jan 7;367(9504):52-6. doi: 10.1016/S0140-6736(06)67924-5.
PMID: 16399153BACKGROUNDRunyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 Apr;57(4):1651-3. doi: 10.1002/hep.26359. No abstract available.
PMID: 23463403BACKGROUNDBucsics T, Schwabl P, Mandorfer M, Peck-Radosavljevic M. Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). J Hepatol. 2016 Jun;64(6):1452-4. doi: 10.1016/j.jhep.2016.01.039. Epub 2016 Feb 23. No abstract available.
PMID: 26916528BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Mohamed Zakaria, Professor
Assiut University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
December 21, 2020
First Posted
December 24, 2020
Study Start
January 1, 2021
Primary Completion
January 1, 2022
Study Completion
March 1, 2022
Last Updated
December 28, 2020
Record last verified: 2020-12